Medication info
Cande Duo Tablets 5/8 mg

Cande Duo Tablets 5/8 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›8mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 202107090 · Approved 2021.10.25 · Insurance code 694003660

Summary

Main use
Treatment of hypertension and heart failure; treatment of dyslipidemia and inhibition of atherosclerosis; prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or longer, up to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Elderly: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Safety and efficacy have not been established in adolescents and children aged 18 years and younger. Safety and efficacy have not been established in adolescents and children aged 18 years and younger.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; treatment of dyslipidemia and inhibition of atherosclerosis; prevention of cardiovascular disease

  • Essential hypertension
  • heart failure
  • impaired left ventricular systolic function
  • poor tolerance to ACE inhibitors
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
View approved original text

This medication is used for patients who are required to take both Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is used for treating essential hypertension and for heart failure patients (especially those with impaired left ventricular systolic function) who require additional help from ACE inhibitors or who have poor tolerance. Rosuvastatin is used as an adjunct to diet in patients with hypercholesterolemia that is unmanageable by diet and exercise, familial hypercholesterolemia, and combined hyperlipidemia. It also lowers cholesterol levels in patients with hypercholesterolemia, delays the progression of atherosclerosis, and assists in the treatment of patients with abnormal beta-lipoproteinemia. In patients at high risk for cardiovascular diseases, it is used to reduce the risk of stroke, myocardial infarction, and arterial revascularization. Therefore, this medication helps improve blood pressure and cardiac function, manage cholesterol, and reduce the risk of cardiovascular diseases.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with careful caution in patients at high risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those receiving hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of 2 weeks or longer, up to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Elderly: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Safety and efficacy have not been established in adolescents and children aged 18 years and younger. Safety and efficacy have not been established in adolescents and children aged 18 years and younger.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Furthermore, women of childbearing potential should use appropriate contraception and it is safer for pregnant or nursing women not to use this medication. It should not be administered to patients with impaired liver function or severe kidney dysfunction, and those with specific genetic metabolic disorders should avoid it. As muscle-related side effects may occur, patients should consult a doctor immediately if they experience muscle pain or weakness, and monitoring of muscle enzyme levels is necessary before and during treatment. Caution is required when administering to elderly patients, those with hyperkalemia, liver disease, or heart disease, as excessive drops in blood pressure can lead to dizziness or fainting. This medication may interact with other antihypertensive agents or specific drugs, so patients should inform their doctor or pharmacist of any medications they are taking. Periodic liver function tests are recommended since signs of liver dysfunction may occur during treatment. Caution is needed as dizziness may occur while driving or operating machinery. In case of overdose, patients should visit a medical facility immediately for appropriate treatment, and there is no specific antidote, so symptomatic treatment will be provided. Keep out of reach of children, and avoid transferring the medication to other containers to prevent misuse or deterioration of quality.

Side effects

headache, pharyngitis, local infection, systemic pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, increased blood sugar, decreased blood sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, chest discomfort, fatigue, inflammation, foreign body sensation, chalazion, periodontitis, musculoskeletal pain, neck pain, nausea, orthostatic dizziness, dizziness, arthralgia, myalgia, low back pain, weakness, fever, paresthesia, tachycardia, palpitations, hyperkalemia, hyponatremia, hypoglycemia, thrombocytopenia, jaundice, hepatitis, rash, urticaria, angioedema, rhabdomyolysis, myopathy, myositis, hematuria, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, increased tension, facial flushing, weight gain, facial edema, thirst, sleep disturbances, decreased libido, memory loss, appetite loss, appetite increase, tinnitus, taste distortion, erectile dysfunction, angioedema, constipation, pancreatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, edema, depression, insomnia, nightmares, interstitial lung disease, sexual dysfunction, gynecomastia, fatal liver failure, non-fatal liver failure, cognitive decline, amnesia, memory impairment, confusion, severe muscle weakness, ocular muscle weakness, hypotension, renal impairment, increased creatinine, increased urea, increased potassium, elevated ALT, elevated AST, elevated γ-GTP, liver dysfunction, jaundice, arthralgia, muscle cramps, gout, syncope, generalized pain

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.